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In patients with diabetes, the presence of persistent
microalbuminuria is an established predictor of develop-
ment of overt diabetic nephropathy, progressive renal in-
sufficiency and increased risk of cardiovascular disease, in
both type 1 and 2 diabetes [1–4]. Approximately 30% of
type 1 diabetic patients may develop diabetic nephropa-
thy within 25 years of diabetes, although recent data sug-
gest a declining incidence [5, 6]. In the original studies
demonstrating the predictive value of microalbuminuria,
up to 80% of patients with microalbuminuria progressed
to overt diabetic nephropathy.
Recently, it has been suggested that microalbuminuria
may not be as sensitive and specific as predictor of di-
abetic nephropathy as originally suggested [7]. Obser-
vational studies have found regression from microalbu-
minuria to normoalbuminuria in a substantial fraction of
patients with type 1 diabetes and microalbuminuria [8].
Furthermore, it has been suggested from uncontrolled
studies of patients with long duration of diabetes that
microalbuminuria is not a good predictor of progression
to overt nephropathy in longstanding type 1 diabetic pa-
tients [9].
We conducted a 10-year observational follow-up study
of a large cohort of type 1 diabetic patients to eluci-
date putative risk markers for the progression from mi-
croalbuminuria to overt diabetic nephropathy. We have
previously demonstrated the presence of poor glycemic
control, retinopathy, smoking, and elevated urinary al-
bumin excretion within normal range to be predictors
of development of microalbuminuria [10]. In the present
study, the factors involved in progression from microal-
buminuria to overt nephropathy are evaluated, as well as
the predictive value of microalbuminuria in longstand-
ing type 1 diabetes for the development of overt diabetic
nephropathy. In addition, we wanted to determine the
annual rate of progression in urinary albumin excretion
rate in microalbuminuric patients.
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METHODS
We asked all 1024 patients with type 1 diabetes that sat-
isfied certain criteria and were attending the outpatient
clinic at Hvido¨re Hospital (now Steno Diabetes Center)
in 1984 to participate [11]. The criteria were age 18 years
or older, duration of diabetes 5 years or more, and age
40 years or under at onset of diabetes. Forty-two patients
were excluded because they had been referred by one of
us (H.H.P.) and one or more 24-hour urine collections
were obtained from 957 (97%) of the remainder. Eigh-
teen patients were excluded from follow-up. Thus, 939
patients were followed up until January 1, 1995 or death
(N = 207) or emigration (N = 36). At baseline, 181 had
microalbuminuria (31 to 299 mg/24 hours) and during fol-
low up a further 153 patients of the 593 patients with nor-
moalbuminuria (≤30 mg/24 hours) at baseline developed
microalbuminuria. Clinical data at baseline are presented
in Table 1. All the patients were white. Patients gave in-
formed consent and the local ethics committee approved
the study.
Procedures and methods in the baseline study were as
described [11]. Twenty-four–hour urinary albumin excre-
tion was measured in sterile urine by radioimmunoassay
as they were obtained, with a sensitivity of 0.5 mg/L and
an interassay coefficient of variation of 9%. Measure-
ments were done at baseline and during regular follow-up
in our outpatient clinic. Microalbuminuria and macroal-
buminuria were defined as urinary albumin excretion 31
to 299 mg and 300 mg or more, respectively, per 24 hours
in at least two out of three consecutive samples [12]. Urine
samples were taken routinely at least once a year. When
values were abnormal, samples were requested at all sub-
sequent visits. Time of onset of microalbuminuria and
overt nephropathy during follow-up were defined as the
first recorded positive urine sample in a series of three
fulfilling the above criteria.
Arterial blood pressure was measured once on the
right arm with a standard clinical sphygmomanometer
(cuff size 25 × 12) after 10 minutes’ sitting. During fol-
low up blood pressure was measured at least yearly; hy-
pertension was defined and treated according to World
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Table 1. Clinical data at baseline in 334 type 1 diabetic patients
having or developing microalbuminuria during a 10-year follow-up
period, according to progression to overt diabetic nephropathy
Progressors Nonprogressors
(N = 93) (N = 241)
Men % 56 51
Age years 37 (14) 41 (14)a
Duration of diabetes years 19 (11) 22 (11)a
Hemoglobin A1c % 9.6 (1.9) 9.1 (1.9)a
Retinopathy (none, simplex,
proliferative) %
18/61/21 15/62/93
Arterial blood pressure mmHg
Albuminuria mg/24 hr
Smoker %
Data are mean (SD) or median (range).
aP < 0.05.
Health Organization criteria (≥160/95). Hemoglobin A1c
(HbA1c) concentration was measured at least yearly with
an isoelectric focusing method (normal range 4.1% to
6.1%, data comparable to the Diabetes Control and Com-
plications Trial values) [abstract; Bergstro¨m J, et al, Dia-
betologia 38:A184, 1995]. The same observer carried out
ophthalmoscopy through dilated pupils. Patients were
categorized as having “any” retinopathy in the pres-
ence of background or proliferative retinopathy. Patients
were classified as smokers if they smoked one or more
cigarettes daily in 1984 based on case records. Socioe-
conomic class [I (i.e., university degree) to V (unskilled)]
was determined from length of education and occupation,
based on case record information [13].
Statistical methods
The unpaired t test was used to compare continuous
variables and the v 2 test to evaluate proportions. The
urinary albumin excretion rate was logarithmically trans-
formed before analysis due to its skewed distribution and
is presented as geometric mean and 95% confidence in-
terval. P values <0.05 (two-sided) were considered sig-
nificant.
The annual progression rate for urinary albumin ex-
cretion rate was evaluated by a mixed model. The patient
levels reflect past experiences and were treated as sepa-
rate parameters. The slope of albumin excretion rate on
time was modeled as a function of the explanatory fac-
tors and random variation. The measurements were also
subject to measurement error (including short-term vari-
ation in excretion rate). To avoid the confounding effect
of antihypertensive medication on the progression rate,
only observations prior to initiation of any antihyperten-
sive medication, including diuretics, was included.
Cox’s proportional hazards multiple regression anal-
yses were used to examine the baseline variables pre-
dictive of progression to macroalbuminuria. Results are
described as relative risk (hazard ratio). The models in-
cluded those baseline variables that were a priori consid-
ered to be potentially important predictors of progressors
or that were found to be significantly different at baseline
when we compared the two groups. This included gender,
age at onset of diabetes, presence of retinopathy, arte-
rial blood pressure, log urinary albumin excretion rate,
HbA1c, height, social class, serum creatinine, and smok-
ing. Age at onset of diabetes demonstrated a nonlinear
relationship with the risk for progression, with a mini-
mum of age at onset of approximately 15 years and was
therefore entered in the model as (age at onset – 15)2.
Stepwise backward selection was used. The time scale
was time since diagnosis of diabetes (implying that times
were truncated). The software used was SAS version 6.11,
proc mixed. For each year of follow-up, the median value
for all urine collections during that year was used.
RESULTS
Rate of progression of urinary albumin excretion rate
Based on the 181 patients with microalbuminuria at
baseline, the annual mean (SE) progression rate of uri-
nary albumin excretion rate was found to be 6.2%
(1.7)/year. Due to the confounding effect of antihyperten-
sive medication on the urinary albumin excretion rate we
excluded observations on antihypertensive medication,
and in order to increase the accuracy a minimum of three
measurements without antihypertensive edications were
required. The annual progression rate was then found to
be 11.1% (2.6)/year (N = 117 having at least three mea-
surements without antihypertensive medications).
To evaluate the impact of putative progression promot-
ers (i.e., factors responsible for the variation in progres-
sion rate), a stepwise regression analysis applying mixed
models with progression of albumin excretion rate as the
dependent variable was performed. It revealed that ele-
vated HbA1c was the only factor significantly associated
with faster progression of albumin excretion rate in pa-
tients with microalbuminuria at baseline and not receiv-
ing antihypertensive medications (3.6% change in slope
per 1% change in HbA1c) (P < 0.01). The following inde-
pendent baseline variables were excluded from the final
model: age at onset of diabetes, gender, height, arterial
blood pressure, log albumin excretion rate, retinopathy
(any), smoking (yes/no), social class (I to V) and serum
creatinine.
Progression to overt nephropathy
Patients were followed for up to 10 years, mean (SD)
7.9 years (2.6), and 59 of the 181 patients who had microal-
buminuria at baseline (33%) developed overt diabetic
nephropathy (persistent urinary albumin excretion rate
>300 mg/24 hours). The incidence of overt nephropathy
was dependent on the duration of diabetes, with a max-
imum of 10.2% per year in microalbuminuric patients
with 10 to 15 years of diabetes duration (Fig. 1). Forty-
five percent of patients with duration of diabetes less than
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Fig. 1. Observed incidence (95% confidence
interval) of overt diabetic nephropathy in 181
type 1 diabetic patients with microalbumin-
uria at baseline followed for up to 10 years.
Table 2. Cox regression analysis of risk factors for progression to
overt nephropathy in type 1 diabetic patients with microalbuminuria,
censored at onset of antihypertensive therapy (93 events, N = 334)
Relative risk (95% CI) P value
Log10 U-albumin excretion rate
mg/24 hr
2.07 (1.31–3.26) <0.01
Hemoglobin A1c % 1.13 (1.03–1.24) <0.01
(age at onset-15)2 1.0015 (1.0003–1.0028) <0.02
Sex, duration of diabetes, arterial blood pressure, S-creatinine, height,
retinopathy, smoking, and social class were not included in the final model.
15 years progressed to overt nephropathy in contrast
to 26% of patients with duration of diabetes exceeding
15 years (P = 0.01). At baseline 16% were on antihy-
pertensive medications, and at end of follow-up it was
76% [mainly angiotensin-converting enzyme (ACE) in-
hibition].
When all 334 patients with microalbuminuria at base-
line or during follow-up were evaluated, 93 patients
(28%) progressed to overt diabetic nephropathy. To eval-
uate the impact of putative progression promoters on
time to development of overt nephropathy, a Cox regres-
sion analysis of progression to diabetic nephropathy (93
cases), including all patients with microalbuminuria at
baseline or during follow-up (N = 334) using the same pu-
tative predictors of progression, and excluding patients at
start of antihypertensive medications, demonstrated ele-
vated HbA1c (P < 0.01), urinary albumin excretion rate
(P < 0.001), and (age at onset – 15)2 (P < 0.01) as predic-
tors (Table 2). Patients were divided based on quintiles of
urinary albumin excretion rate to illustrate the impact of
the level of urinary albumin excretion rate on rate of pro-
gression to overt nephropathy (Fig. 2) demonstrating that
particularly in patients with values exceeding 100 mg/24
hours was there an increased risk for progression to overt
nephropathy.
A regression to persistent normal urinary albumin ex-
cretion rate at the end of follow-up was seen in 53 (16%)
of the patients who had microalbuminuria at baseline or
developed persistent microalbuminuria during the follow
up period, in 55% of the cases this was seen after initiation
of antihypertensive treatment.
DISCUSSION
During 10-year follow-up the presence of microalbu-
minuria (urinary albumin excretion rate 31 to 299 mg/24
hours) predicted progression to overt nephropathy (≥300
mg/24 hours) in 33% of type 1 diabetic patients or an inci-
dence of 3.3 per 100 person-years, whereas 16% of the pa-
tients had regressed to normoalbuminuria (drug induced
in approximately half of the patients). Levels of HbA1c
and urinary albumin excretion rate at baseline were as-
sociated with the progression to overt nephropathy and
a nonlinear effect of age at onset was observed with the
smallest risk for progression with age at onset of 15 years.
We observed an annual increase in urinary albumin ex-
cretion rate of 11.1% in patients who were not receiving
antihypertensive therapy, whereas it was 6.2% if obser-
vations on antihypertensive medication were included,
and glycated hemoglobin was the only factor being sig-
nificantly associated with the increase in urinary albumin
excretion.
The initial observational studies evaluating the risk
for progression to overt nephropathy in microalbumin-
uric type 1 diabetic patients indicated that the risk was
approximately 80% within 6 to 14 years (i.e., 6 to 10
per 100 person-years) [1, 2, 14], but these studies in-
cluded patients with shorter duration of diabetes com-
pared to the present study. Subsequent observational and
intervention studies have found highly varying rates of
progression ranging from 2 [15] to 13 [16] per 100 person-
years. The difference in progression rates is probably ex-
plained by differences in diagnostic criteria for micro- and
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Fig. 2. Cumulative incidence of overt dia-
betic nephropathy according to quintiles of
urinary albumin excretion rate (UAER) level
in 334 microalbuminuric type 1 diabetic pa-
tients.
macroalbuminuria, as well as differences in progression
promoters as metabolic control, diabetes duration, blood
pressure, and antihypertensive therapy. We have applied
generally accepted diagnostic criteria [12, 17]. Some stud-
ies have questioned the predictive value of the presence
of microalbuminuria [7, 18] and microalbuminuria was
even suggested to be a transient phenomenon in most
patients in an observational study of 386 patients where
58% of microalbuminuric patients regressed to normoal-
buminuria [8]; however, the regression was transient in
many patients and follow-up was only up to 6 years. In
the present study with up to 10 years’ follow-up, only 16%
regressed to persistent normoalbuminuria, and this was
most likely explained by antihypertensive medication in
more than half of these patients. This is in accordance
with our long-term study of an inception cohort of type 1
diabetic patients where only 13% obtained spontaneous
regression to normoalbuminuria [19].
We observed that the predictive value of microalbu-
minuria was highly dependent on duration of diabetes,
with the risk for development of overt proteinuria be-
ing up to 10% per year in patients with 10 to 15 years’
duration of diabetes, but even in patients with very long
duration of diabetes, the presence of microalbuminuria
was associated with a risk for development of overt
nephropathy of 4% per year. Twenty-six percent of pa-
tients with more than 15 years’ duration progressed to
overt nephropathy, in contrast to 45% of patients with
shorter duration of diabetes. In a 10-year follow-up study
of 18 patients from Finland [9], they also observed that
28% of patients with microalbuminuria and more than
15 years diabetes duration developed overt nephropa-
thy; however, this study was uncontrolled as they only in-
cluded patients with long duration of diabetes. A similar
small and uncontrolled study from the United Kingdom,
including patients with more than 30 years of diabetes
[20] found 32% of 19 patients with microalbuminuria de-
veloped overt proteinuria during 7 years’ follow-up. This
suggests that microalbuminuria remains a good predic-
tor for progression to overt nephropathy even in patients
with long diabetes duration.
In accordance with previous observational studies poor
glycemic control was associated with a fast annual rate of
progression in albuminuria and high risk of progression
to overt nephropathy [9, 15, 21–23]. In randomized trials
it has, however, been difficult to demonstrate an effect
of intensive metabolic control on progression to overt
nephropathy [24, 25], maybe due to inadequate sample
sizes or insufficient separation in glycemic control be-
tween groups. This is in contrast to the beneficial effect
demonstrated on the development of microalbuminuria
in normoalbuminuric subjects [26, 27].
The present observational study was not designed to
evaluate the effect of antihypertensive medication in mi-
croalbuminuric patients, but the annual rate of progres-
sion in urinary albumin excretion was only 6.2 when mea-
surements on antihypertensive medication was included
compared to 11.1% increase per year when measure-
ments on antihypertensive medication was excluded, and
during follow-up the frequency of patients on antihyper-
tensive medication increased from 16% to 76% which
probably contributes to the lower rate of progression to
overt nephropathy compared to the initial studies, as the
beneficial effect on progression has been demonstrated in
several randomized controlled trials [16, 28, 29]. Despite
this arterial blood pressure at baseline was not associated
with the risk for progression to overt nephropathy, in ac-
cordance with other observational studies [15, 23, 24]. It is
possible that changes in blood pressure are only apparent
very close to the development of overt nephropathy, it is
also possible that changes in blood pressure are so small
that more sensitive methods than office blood pressure
measurements should be used, such as 24 hours ambula-
tory blood pressure measurements [30]. It has also been
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suggested that the relationship between blood pressure
and albumin excretion depend on the metabolic control
[31].
The main analyses of this paper use the time since di-
agnosis of diabetes as the basic time scale, the analyses
were also performed with time since baseline as the time
scale. The advantage of the slope analysis is that it is not
sensitive toward the choice of time scale.
CONCLUSION
Our study supports that the presence of microalbumin-
uria is associated with a high risk for progression to overt
nephropathy. The risk depends on duration of diabetes,
but even in patients with long duration of diabetes there is
a substantial risk. The study also suggests that potentially
modifiable risk factors such as urinary albumin excretion
rate and poor metabolic control predict the progression
of microalbuminuria in type 1 diabetic patients.
Reprint requests to Peter Rossing, Steno Diabetes Center, Niels
Steensens Vej 2, 2820 Gentofte, Denmark.
E-mail: pro@steno.dk
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